Sirnaomics Ltd. [2257.HK]

(Incorporated in the Cayman Islands with limited liability)

Interim Data Release

Disclaimer

By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by representatives of Sirnaomics Ltd. (the “Company”) for use in presentations by the Company at investor meetings and does not constitute a recommendation regarding the securities of the Company.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of the Company's advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially.

This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm.

The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as “will”, “expects” and “anticipates” and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not rely on these forward-looking statements. The Company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered, sold or delivered within the United States or to U.S. persons absent registration under or an applicable exemption from the registration requirements of the Securities Act.

This presentation and the information contained herein do not constitute or form part of any offer for sale or issuance of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company. This presentation and the information contained herein are strictly confidential, are being furnished to you solely for your information and may not be reproduced in any form or redistributed in any manner to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the United States, Canada, Australia, Japan, Hong Kong or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

No invitation is made by this presentation or the information contained herein to enter into, or offer to enter into, any agreement to purchase, acquire, dispose of, subscribe for or underwrite any securities or structured products, and no offer is made of any shares in or debentures of a company for purchase or subscription.

By reviewing this presentation, you are deemed to have represented and agreed that you and any customers you represent are either (a) a “qualified institutional buyer” (within the meaning of Rule 144A under the Securities Act), or (b) not a U.S. person (as defined in Regulation S under the Securities Act) and are outside of the United States and not acting for the account or benefit of a U.S. person (as defined in Regulation S under the Securities Act).

Advancing Oncology Programs with the PNP Platform

	Candidate	Gene Targets	Indications	Delivery Platform	Pre-clinical	IND Enabling	IND	Phase I	Phase II	Phase III	Rights
Oncology	STP705*	TGF-β1/COX-2	isSCC	PNP-IT	US		China (MRCT)[2]				Global
			Facial isSCC		US						Global
			BCC		US						Global
			Liver Cancer[1] (Basket) **		US		China (MRCT)[3]				Global
			Liver Cancer, combo with anti-PD-(L)1[5]		US						Global
	STP707	TGF-β1/COX-2	Multiple solid tumors		US		China (MRCT)[4]				Global
			cSCC	PNP-IV	US						Global
			NSCLC		US						Global
			Liver Cancer, cSCC, NSCLC, combo with anti-PD-(L)1[5]		US						Global
	STP355	TGF-β1/VEGFR2	Pan Cancer		US						Global
	STP369	BCL-xL/MCL-1	Head & Neck Cancer / Bladder Cancer	PNP-IT	US						Global
	STP779	TGF-β1/Sulf-2	Liver Cancer/ Lung Cancer/Pancreatic Cancer	PNP-IV	US						Global
Fibrosis	STP705*	TGF-β1/COX-2	Keloid Scarless Healing	PNP-ID				US			Global
			Hypertrophic Scarring					US			Global
							China (MRCT)				
							China				
	STP707	TGF-β1/COX-2	Liver Fibrosis (PSC)	PNP-IV				US			Global
							China（MRCT）				
			Lung Fibrosis				US				Global
Medical Aesthetics	STP705*	TGF-β1/COX-2	Fat sculpting	PNP-ID			US				Global
Antiviral	STP702	M1/PA	Influenza	Airway / PNP-IV			US				OL China
	RIM730[6]	SARS-CoV-2	Covid-19 vaccine	LNP Intramuscular			US				Global
GalAhead™	STP122G	Factor XI	Anticoagulation/Thrombosis	GalAhead™ subcutaneous			US				Global
	STP125G	ApoC3	Hypertriglyceridemia				US				Global
	STP144G	Complement Factor B	Complement-mediated diseases				US				Global
	STP145G	Complement C5	Complement-mediated diseases				US				Global
	STP146G	Complement C3	Complement-mediated diseases				US				Global
	STP247G	Complement CFB/C5	Complement-mediated diseases				US				Global
	STP251G	ApoC3/TMPRSS6	Hemochromatosis & Hypercholesterolemia				US				Global
	STP152G	Non-disclosed	Rare disease				US				Global
	STP136G	Non-disclosed	Hypertension				US				Global
	STP237G	Non-disclosed	Hypertension & Hypercholesterolemia				US				Global
PDoV-GalNAc	STP135G	Non-disclosed	Hypercholesterolemia	PDoV-GalNAc subcutaneous							Global
	STP155G	HBV sequences	HBV								Global

Notes： * *denotes our core product* ** *denotes orphan drug*

1. Liver cancer (basket) includes cholangiocarcinoma, hepatocellular carcinoma, liver metastases etc. 2. We filed our IND in China in June 2021, which is currently awaiting approval from NMPA, for study sites in China. The study sites will be part of a global multicenter clinical trials for our Phase IIb clinical trial for isSCC. 3. We expect to file the IND in Greater China as part of the global multicenter clinical trials. 4. We expect to file the IND solely for HCC in China as part of the global multicenter clinical trials. 5. Studies in combination with anti-PD-(L)1 inhibitors conducted pursuant to collaborations with Innovent and Shanghai Junshi. 6. Research and development conducted by our subsidiary RNAimmune.

Sirnaomics at Value Inflection Point with Multiple Catalysts



Denote milestones achieved

sirnaomics
Advancing RNAi Therapeutics

STP707 – Solid Tumor Phase I Interim Data Discussion

Trial Design

- Multi-center open label, dose escalation and dose expansion tumor basket study to evaluate the safety, tolerability, and anti-tumor activity. **20 participants** with advanced solid tumors who are refractory to standard therapy
- Five total cohorts who will receive escalating doses through IV administration on a 28-day cycle including a 3 mg, 6 mg, 12 mg, 24 mg and 48 mg dosing cohorts. **Interim data is subjects from the 3 mg, 6 mg, and 12 mg dosing cohorts**
- Secondary endpoints are to determine the pharmacokinetics of STP707 and to observe preliminary anti-tumor activity
- **Positive Phase I Clinical Safety data readout for solid tumor treatment.** Passed each of the first 3 cohorts' safety requirements for dose escalation.
- Once maximum tolerated dose or recommended Phase II dose has been established, additional patients will be enrolled to confirm safety and explore anti-tumor activity.

Full report is expected to be ready by 2H 2023 subject to patient enrollment and response

Analysis: Based on Cohort

Patients that received >4 doses exhibit stable disease average # of days



- Average duration stable disease from first treatment
- 12 mg group is ongoing at the time of analysis

	3 mg	6 mg	12 mg
Mean (Days)	63.67	74.17	64.75

Analysis: Anatomical Location

Patients that received >4 doses average stable disease in days per tumor type



- Average duration of stable disease in days per tumor type

	Colon	Liver	Pancreas
Mean (Days)	70.5	89.67	75.00

Analysis: Anatomical Location – Liver

Average number of days stable disease compared to all previous treatments; Patients that received >4 doses; All Patients showed PD with previous Tx



No significant difference between STP707 and prior first and second line therapies

Analysis: Anatomical Location – Pancreas

Average number of days stable disease compared to all previous treatments; Patients that received >4 doses; All Patients showed PD with previous Tx



No significant difference between STP707 and prior first and second line therapies

Analysis: Cancer Type - Melanoma

Patients that received >4 doses; Only selected prior therapies with PD





Patient 104-004 treated with STP707

Note: Data represents draft analysis using the interim analysis table. Only some of the selected prior therapies with PD/unknown are presented (does not encompass entire dataset). Full evaluation by a clinical/biostatistician expert needs to be conducted to verify these results.

Uveal Melanoma subject currently has greater than 150 days on treatment with regression of disease at 26% based on re-staging scan

sirnaomics
Advancing RNAi Therapeutics

STP705 – isSCC Phase IIb Interim Data Discussion

STP705 – isSCC Positive Phase IIb Interim Data

- The two-part, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy, administered as an intralesional injection in subjects with isSCC.
- In the part-one of the study, treated 32 patients with 30 µg/ml, 60 µg/ml and 90 µg/ml of STP705 and 12 patients with 0 µg/ml placebo weekly for 6 week repeated dosing. This interim data is specifically for the part-one of the study with total of 44 patients.
- Positive Phase IIb Clinical Readouts for isSCC treatment
  - Overall, **78%** of subjects across all groups (32 subjects) achieved Histological Clearance
  - One of the three treatment cohorts **achieved 89% histological clearance**
  - **No significant cutaneous skin reactions** and **no** treatment related **AE's or SAE's**, Skin Response Scores improved in 4/5 dosing cohorts and there were no dose limited toxicities noted in the study population

	Histological Clearance
Cohort A: 30 µg/ml N= 9	**89%**
Cohort B: 60 µg/ml N= 12	**75%**
Cohort C: 90 µg/ml N= 11	**73%**
Cohort D: placebo group N= 12	**58%**
Overall result	**78%**



Source: Smart Pharma and public information

- Based on study plan, the part-two of study will include 60 additional subjects receive selected doses or placebo. Enrolled subjects will be randomly allocated to receive STP705 or placebo injection once weekly for six weeks.

With the positive data, evaluation to expand into SCC is being performed

sirnaomics
Advancing RNAi Therapeutics

Q&A